126 related articles for article (PubMed ID: 31509482)
21. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
22. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Jiang T; Zhang Y; Li X; Zhao C; Chen X; Su C; Ren S; Yang N; Zhou C
Eur J Cancer; 2019 Nov; 121():98-108. PubMed ID: 31569068
[TBL] [Abstract][Full Text] [Related]
23. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases.
Wang Z; Yang JJ; Tu HY; Yan HH; Wu YL
Int J Clin Oncol; 2020 Feb; 25(2):267-273. PubMed ID: 31587134
[TBL] [Abstract][Full Text] [Related]
25. Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer.
Carroll NM; Delate T; Menter A; Hornbrook MC; Kushi L; Aiello Bowles EJ; Loggers ET; Ritzwoller DP
J Oncol Pract; 2015 Sep; 11(5):356-62. PubMed ID: 26060223
[TBL] [Abstract][Full Text] [Related]
26. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Xing P; Mu Y; Wang Y; Hao X; Zhu Y; Hu X; Wang H; Liu P; Lin L; Wang Z; Li J
Thorac Cancer; 2018 Jul; 9(7):805-813. PubMed ID: 29768721
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study.
Kosty MP; Wozniak AJ; Jahanzeb M; Leon L; Fish S; Hazard SJ; Lynch TJ
Target Oncol; 2015 Dec; 10(4):509-16. PubMed ID: 25559289
[TBL] [Abstract][Full Text] [Related]
28. Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens.
Yan LZ; Dressler EV; Adams VR
J Oncol Pharm Pract; 2018 Apr; 24(3):209-217. PubMed ID: 29284349
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
30. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Drakaki A; Dhillon PK; Wakelee H; Chui SY; Shim J; Kent M; Degaonkar V; Hoang T; McNally V; Luhn P; Gutzmer R
Oncoimmunology; 2020 Oct; 9(1):1824645. PubMed ID: 33101774
[TBL] [Abstract][Full Text] [Related]
31. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
32. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data.
Feliciano J; Gardner L; Hendrick F; Edelman MJ; Davidoff A
Lung Cancer; 2015 Jan; 87(1):59-64. PubMed ID: 25443272
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
34. Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data.
John A; Yang B; Shah R
Adv Ther; 2021 Mar; 38(3):1552-1566. PubMed ID: 33537872
[TBL] [Abstract][Full Text] [Related]
35. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting.
Shah M; Winfree KB; Peterson P; Gruschkus SK; Eaddy M; Green MR
Lung Cancer; 2013 Oct; 82(1):121-7. PubMed ID: 23973203
[TBL] [Abstract][Full Text] [Related]
37. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
38. [Advances in Bevacizumab Therapy for Non-small Cell Lung Cancer
with Brain Metastases].
Qu L; Geng R; Song X
Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):515-8. PubMed ID: 27561800
[TBL] [Abstract][Full Text] [Related]
39. Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.
Menter AR; Carroll NM; Sakoda LC; Delate T; Hornbrook MC; Jain RK; Kushi LH; Quinn VP; Ritzwoller DP
Clin Lung Cancer; 2017 Mar; 18(2):189-197.e3. PubMed ID: 27637408
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
Matikas A; Kentepozidis Ν; Ardavanis A; Vaslamatzis M; Polyzos A; Emmanouilides Ch; Katsaounis P; Koinis F; Xynogalos S; Christopoulou A; Ziras N; Tegos T; Prinarakis E; Hatzidaki D; Georgoulias V; Kotsakis A;
Cancer Chemother Pharmacol; 2016 Aug; 78(2):369-76. PubMed ID: 27335027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
